Stomach Cancer
Make an Inquiry
Accelerating Stomach Cancer Drug Development

Cancer of the stomach remains a formidable clinical challenge, characterized by complex biology and limited therapeutic options. Alfa Cytology stands at the forefront of preclinical drug development, offering specialized expertise in the advancement of novel therapeutics targeting gastric malignancies. Leveraging a fully integrated platform, Alfa Cytology provides end-to-end preclinical solutions spanning target validation, lead optimization, pharmacology, toxicology, and IND-enabling studies. Our scientific team combines deep oncology experience with cutting-edge technologies, including advanced in vitro and in vivo models that closely mimic the tumor microenvironment of gastric cancers. Alfa Cytology’s rigorous approach ensures data integrity, reproducibility, and adherence to global regulatory standards, supporting a seamless transition from discovery to clinical development. With a proven track record in oncology drug development and a steadfast commitment to scientific excellence, Alfa Cytology accelerates the path to first-in-class and best-in-class therapies for stomach cancer. Partner with Alfa Cytology to drive innovation and translate scientific breakthroughs into meaningful clinical outcomes for patients worldwide.

What is Stomach CancerTargets for Stomach CancerDrug Discovery and Development ServicesWhy Choose Us

What is Stomach Cancer

Stomach cancer, or gastric cancer, is a malignant tumor originating from the lining of the stomach. Its development is multifactorial, often beginning with chronic inflammation—most notably from Helicobacter pylori infection—progressing through stages such as atrophic gastritis, intestinal metaplasia, and dysplasia before evolving into carcinoma. Other risk factors include high salt and preserved food intake, smoking, genetic predisposition, and hereditary syndromes. The majority of cases are adenocarcinomas, which are further divided into intestinal and diffuse subtypes based on histology. Key molecular alterations, such as mutations in CDH1 and TP53, contribute to tumorigenesis. Less common types include gastrointestinal stromal tumors (GISTs), lymphomas, carcinoid tumors, and squamous cell carcinoma. Clinically, stomach cancer often presents with nonspecific symptoms like indigestion, weight loss, anorexia, and abdominal pain, leading to late-stage diagnoses. Advanced disease may cause obstruction, gastrointestinal bleeding, or metastasis. Diagnosis relies on upper gastrointestinal endoscopy with biopsy, histopathological analysis, and imaging studies such as CT, MRI, and endoscopic ultrasound for accurate staging. Treatment depends on the stage and molecular characteristics, and may include surgery, chemotherapy, targeted therapies (such as trastuzumab and disitamab vedotin for HER2-positive tumors, or claudiximab for Claudin 18.2-expressing cancers), and immunotherapies like tislelizumab and cadonilimab. Early detection and tailored treatment are critical for improving outcomes.

Launched Drugs

Structure Generic Name CAS Registry Number Molecular Formula
claudiximab; zolbetuximab (Rec INN; USAN); zolbetuximab-clzb 1496553-00-4
cadonilimab (Rec INN; USAN) 2233593-44-5
img-2136633-23-1-disitamab-vedotin-rec-inn-usan disitamab vedotin (Rec INN; USAN) 2136633-23-1 C68 H106 N11 O15 R S
trastuzumab; trastuzumab-strf
img-1826843-81-5-fam-trastuzumab-deruxtecanfam-trastuzumab-deruxtec [fam-]trastuzumab deruxtecan; fam-trastuzumab deruxtecan-nxki; trastuzumab deruxtecan (Rec INN; USAN) 1826843-81-5 C52 H57 F N9 O13 R S
tislelizumab (Rec INN; USAN); tislelizumab-jsgr 1858168-59-8
trastuzumab; trastuzumab-qyyp
trastuzumab
trastuzumab; trastuzumab-dttb

Learn More

Targets for Stomach Cancer

Targets in Clinical or Later Phases of Development

Target Name Gene Symbol
ATP binding cassette subfamily B member 1 ABCB1
erb-b2 receptor tyrosine kinase 2 ERBB2
DNA topoisomerase I TOP1
dihydropyrimidine dehydrogenase DPYD
programmed cell death 1 PDCD1
ret proto-oncogene RET
thioredoxin TXN
kinase insert domain receptor KDR
uridine monophosphate synthetase UMPS
Tubulin

Stomach cancer is driven by a complex interplay of molecular targets that regulate tumor growth, survival, immune evasion, and drug resistance. Key oncogenic drivers include receptor tyrosine kinases such as ERBB2 (HER2), FGFR2, and RET, which activate downstream signaling pathways like PI3K/AKT and MAPK, promoting proliferation and metastasis. Immune checkpoint molecules, notably PD-L1 (CD274) and PD-1 (PDCD1), enable tumor cells to escape immune surveillance. Cell adhesion and invasion are mediated by proteins such as CLDN18 and EPCAM, whose dysregulation facilitates metastatic spread. Additionally, angiogenesis is orchestrated by KDR (VEGFR2), supporting tumor vascularization, while chemoresistance is largely attributed to the efflux transporter ABCB1. Enzymes involved in nucleotide metabolism and DNA synthesis, including DPYD, TOP1, TYMP, TYMS, and UMPS, are essential for tumor proliferation and are central to the action and resistance of cytotoxic chemotherapy.

Learn More

Drug Discovery and Development Services

In Vitro Efficacy Testing ServicesIn Vivo Model DevelopmentPK/PD Study ServicesIn Vivo Toxicity Assessment ServicesBiomarker Analysis Services
In Vitro Efficacy Testing Services

Online Inquiry

Our In Vitro Efficacy Testing Service for stomach cancer accelerates drug discovery through advanced cell-based and biochemical assays targeting key pathways including PD-1/PD-L1, HER2, FGFR2, Claudin 18, and STAT3. Utilizing flow cytometry, FACS, ELISA, chemiluminescence, and biosensor platforms, we provide robust assessment of compound potency, binding affinity, and mechanism-of-action. We measure critical pharmacological parameters such as IC-50, EC-50, Kd, and MIC, ensuring precise candidate profiling. Our comprehensive approach supports lead optimization, risk assessment, and informed decision-making, delivering high-quality, reproducible data to advance stomach cancer therapeutic development efficiently and effectively.

Cd274 Molecule Claudin 18
Dna Topoisomerase I Erb-B2 Receptor Tyrosine Kinase 2
Fibroblast Growth Factor Receptor 2 Kinase Insert Domain Receptor
Mechanistic Target Of Rapamycin Kinase Programmed Cell Death 1
Signal Transducer And Activator Of Transcription 3

Learn More

Why Choose Us

Choosing Alfa Cytology means partnering with a company that brings specialized expertise and a deep commitment to advancing the field of cancer, stomach research and drug development. At Alfa Cytology, our professional teams consist of highly experienced scientists and researchers who are dedicated to delivering innovative solutions for preclinical drug development. We utilize advanced technology platforms and state-of-the-art facilities to ensure that every project benefits from the latest scientific advancements. Alfa Cytology has established a strong track record of reliability and excellence, consistently providing high-quality preclinical services that support the development of new therapeutics for cancer, stomach. Our rigorous adherence to quality standards and strict regulatory compliance ensures that all studies are conducted with the utmost integrity and precision. Above all, Alfa Cytology is driven by a passion to make a meaningful impact in the fight against cancer, stomach, and we are fully committed to supporting our partners in bringing effective new treatments to patients in need. Partner with Alfa Cytology for professionalism, reliability, and a shared vision for better therapeutics.

FAQs for Our Services

Q: What are the main preclinical research challenges specific to developing drugs for stomach cancer?

A: Stomach cancer presents unique preclinical research challenges, including the heterogeneity of tumor subtypes, the complexity of the tumor microenvironment, and the lack of robust animal models that faithfully recapitulate human disease. Our company addresses these challenges by employing advanced in vitro 3D gastric organoid models and patient-derived xenograft (PDX) models, enabling us to better predict clinical efficacy and optimize candidate selection.

Q: What are the key regulatory considerations during preclinical development of stomach cancer drugs?

A: Regulatory agencies require comprehensive safety, pharmacokinetic, and efficacy data before approving clinical trials for stomach cancer drugs. This includes demonstrating target engagement, dose selection rationale, and toxicology profiles in relevant models. Our team ensures full compliance with FDA and EMA guidelines, providing detailed documentation and consultation to streamline the Investigational New Drug (IND) application process.

Q: What technical expertise is required for effective preclinical research in stomach cancer drug development?

A: Effective preclinical research for stomach cancer drugs requires expertise in molecular biology, pharmacology, and oncology, as well as proficiency in advanced imaging, biomarker identification, and high-throughput screening. Our company leverages multidisciplinary teams and state-of-the-art technologies to support mechanism-of-action studies, lead optimization, and translational research.

Q: How long does the preclinical development process typically take for stomach cancer drugs, and what are the cost considerations?

A: The preclinical development phase for stomach cancer drugs typically spans 18 to 36 months, depending on the complexity of the compound and required studies. Costs can range from $2 million to $10 million, influenced by the number of efficacy and safety studies, model selection, and regulatory requirements. We offer tailored project management and budgeting to optimize timelines and cost-effectiveness for our clients.

Q: What are the critical success factors for preclinical development of stomach cancer drugs?

A: Key success factors include selecting clinically relevant models, identifying predictive biomarkers, ensuring robust safety and efficacy data, and maintaining regulatory compliance. Our company’s integrated approach combines cutting-edge science, regulatory expertise, and project management to maximize the probability of successful transition from preclinical to clinical development.

Make an Inquiry
Important Links
Get in Touch with Us

Copyright © 2026 Alfa Cytology. All rights reserved.